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Abstract
Objectives: Most non-screen-detected cervical cancers are advanced stage. We assess the potential for cytology to expedite
diagnosis when used outside of routine call and recall screening for cervical cancer.
Methods: Two cohorts of women with cytology that did not appear to have been taken as part of routine screening, nested
within a census of cervical cytology, in England between April 2007 and March 2010 were studied: 93,322 women aged 40–69 at
first cytology, and 14,668 women aged570. The diagnostic performance of high grade cervical squamous intraepithelial lesion
(HSIL) or worse cytology was estimated. We also estimated case-fatality from stage distribution in women aged566 with and
without cytology in the year prior to diagnosis.
Results: There were 259 cancers diagnosed in women aged 40–69 at first cytology, and 78 in women aged570. The sensitivity
of cytology5 HSIL for cancer was 89% and 83% respectively, and the number of women needed to test to identify one cancer
was 404 (95% confidence interval [CI]: 355–462) and 226 (95% CI: 177–292) respectively. Women aged 566 with cytology
within a year of diagnosis had earlier stage cancers than those without, corresponding to a 17–22% reduction in case fatality.
Conclusions: Cervical cytology is an excellent identifier of cancer among women tested outside routine screening call and
recall. Its use as a triage tool, for instance in women with vague gynaecological symptoms, could facilitate earlier stage diagnosis
and reduce cervical cancer mortality.
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Introduction
Global strategies for cervical cancer control include vac-
cination against high risk HPV types, population screen-
ing, and early-stage diagnosis.1 While the ﬁrst two are
currently given appropriate consideration, strategies for
down-staging non screen-detected cervical cancer have
been overlooked. Cervical cancer in those who are too
young to beneﬁt from screening, who are no longer oﬀered
screening, or who have not been screened recently is often
diagnosed at advanced stage and has poor prognosis.
The aim of cervical screening is to prevent cervical
cancer, through identifying and treating pre-invasive cer-
vical lesions. Additionally, screening can lead to the early
diagnosis of cervical cancer, though that is not its main
focus, and this has not been explored. In England, it has
been shown that one cancer is diagnosed for every 2726
women screened,2 and that the sensitivity of screening
cytology (even at a cut-oﬀ of high-grade cytology) to inva-
sive cancer is high.
This paper considers the use of cervical cytology as an
aid to diagnosis of invasive cancer, with the aim of down-
staging cancers, outside of routine call and recall for
cervical screening. We show the distribution of cytology
results (both in all women with cytology and in those with
cervical cancer) for two groups of women in whom cytol-
ogy was unlikely to have been conducted for screening
alone; women whose ﬁrst cytology test was carried out
aged 40–69, and women with cytology aged 570 (ie. no
longer oﬀered cervical screening). We also compare the
stage distribution in women beyond the age of last screen-
ing invitation with and without cytology in the year prior
to diagnosis, and estimate the diﬀerence in case fatality.
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Methods
We studied a retrospective cohort of women in the general
population who had cervical cytology taken in the 12
months prior to a diagnosis of cervical cancer, between
April 2007 and March 2010. Data for a second cohort, all
women who had cytology, was available from an extract
of the national screening database (Exeter system, taken in
October/November 2010), including monthly attendances
to the screening programme from April 2007 to March
2010.3 This resulted in a census of cytology results.
Information in this extract included the women’s age in
5-year groups, category of invitation (eg. routine recall (3
or 5 years after a negative screen, depending on age), early
recall after an abnormality, surveillance after treatment)
and test result. All cervical cytology was read using British
Society for Clinical Cytology (BSCC) terminology in
laboratories subject to national accreditation and quality
assurance. A comparison between the British and the
Bethesda terminology is given by the National Cancer
Screening Service.4
Data from the National Audit of Invasive Cervical
Cancers in England was used for the results of cytology
in women with cervical cancer.5–7 We excluded all follow-
up tests. For women with cervical cancer we deﬁned the
‘index test’ as the ﬁrst test within 12 months of diagnosis.
This time period was chosen to allow time for diagnosis
following early (6-month) recall triggered by low-grade
cytology, whilst trying to ensure that the cancer was
already present at the time of cytology. In both women
with cancer and in the general population, cytology taken
due to an earlier abnormal result (recall cytology) was
excluded.
We considered two groups of women in whom cytology
was outside of routine call and recall for cervical screen-
ing: those who had cytology taken age 570 (‘post-
screening’), who were not on follow up for a previous
abnormal result; and women who had their ﬁrst cytology
test at age 40–69 (‘late prevalent test’). Routine screening
in England ceases at a woman’s 65th birthday, but women
invited at 64 may be screened at 65, and women with
abnormal screening tests (or colposcopy) in their 60s
may continue to have cervical cytology in their mid 60s.
It is therefore likely that the majority of tests in women
aged 65–69 would be related to the screening programme,
rather than being symptomatic. By contrast virtually all
cytology taken aged570 would not be related to a screen-
ing invitation.
Additionally, we compare the age-adjusted stage distri-
bution of a third cohort of women, those diagnosed with
cervical cancer aged 66 and over (ie. after routine screen-
ing ceases in England) between April 2007 and March
2012, by whether they had cytology within 12 months of
diagnosis. In this group, the date range of diagnosis was
extended, to include more cancers in this cohort. Stage
was not recorded for 24% of these women. Two methods
of assigning stage to those with unknown stage were con-
sidered. The ﬁrst used the stage distribution for all women
with known stage; the second did this separately for those
with and without cytology in the year before diagnosis.
This was combined with 5-year relative survival data from
SEER (Surveillance, Epidemiology, and End Results8) to
estimate the reduction in case fatality that could be
achieved if all women of this age had cytology prior to
their index test. SEER data from the USA were used, as
survival data by stage and age are not readily available for
England. For comparative purposes, we also used English
stage-speciﬁc survival data, which are not available by
age.9 Finally, we compared the stage distribution across
age groups in women aged 540 who did not have cytol-
ogy in the 12 months before diagnosis.
The positive predictive values (PPVs) were calculated
by dividing the number of cancers diagnosed with a given
index test result by the number of cytology tests during the
same period with that same test result. The number of
women needed to test (NNT) is the number of cytology
tests divided by the number of cancers diagnosed follow-
ing moderate or worse cytology. The 95% conﬁdence
intervals (CI) for the NNT and the PPV were calculated
assuming that the number of cancers diagnosed from the
number of cytology tests carried out had a binomial dis-
tribution.10 Analyses were carried out in STATA 12
(StataCorp. College Station, Texas, USA).
Results
Between 1 April 2007 and 31 March 2010 93,322 cytology
tests were conducted in the cohort of women whose ﬁrst
cytology test was at age 40–69 (late prevalent test), and
14,668 for women aged 570 (post-screening). There were
259 women diagnosed with cervical cancer within a year
of their ﬁrst cytology aged 40–69, and 78 women aged
570, who also had a cytology test within 12 months of
diagnosis, during the same period. The prevalence of
cancer among late prevalent test women was 2.8 per
1000, and 5.3 per 1000 for post-screening women. In the
census of cytology results, 2.5% of the tests were high
grade (moderate or worse, equivalent to high grade cer-
vical squamous intraepithelial lesion (HSIL)þ) for post-
screening women, including 2.3% severe or worse
(Table 1a), and the corresponding numbers were 1.4%
and 1.1% in late prevalent test women (Table 1b). In
post-screening women 89.1% of tests were negative
(Table 1a) and 90.8% were negative in late prevalent
test women (Table 1b). In post-screening women 5.5%
of tests were inadequate (Table 1a); 3.6% were inadequate
in late prevalent test women (Table 1b). The NNT to
identify one cancer (based on referring women with a
result of moderate or worse) in late prevalent test
women was 404 (95% CI: 355–462) and 226 (95% CI:
177–292) in post-screening women.
The sensitivity of moderate or worse cytology for
cancer was 83% (95% CI: 73%–91%) in post-screening
women and 89% (95% CI: 85%–91%) in late prevalent
test women. The PPV for cervical cancer of a query inva-
sive report was over 35% in both groups (Table 1). The
PPV of a report of query glandular neoplasia was between
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6% and 8%, and for a report of severe dyskaryosis was
between 15% and 17% (Table 1). The PPV of moderate
dyskaryosis was much higher for post-screening women
than for late prevalent test women (13.0% vs. 3.9%,
p¼ 0.026). The receiver operating characteristic (ROC)
curves are shown in Figure 1, with an area under the
curve of 96.2% (95% CI: 93.5%–98.9%) for post-screen-
ing women and 98.7% (95% CI: 98.1%–99.3%) for late
prevalent test women.
Table 2 shows the stage distribution of women diag-
nosed with cervical cancer aged566, by whether they had
cytology in the 12 months before diagnosis, excluding any
women who had an abnormal result on their previous
cytology test. Women with cytology in the 12 months
prior to diagnosis were diagnosed at an earlier stage
than women without. If the stage distribution in women
without cytology were to be changed to the distribution in
women with cytology, their case fatality could be reduced
by 17.3%–26.4% (depending on assumptions regarding
the stage distribution in those with unknown stage,
Table 2). The stage distribution for women aged 540
without cytology in the 12 months before diagnosis is
largely independent of age (result not shown).
Discussion
We have shown elsewhere that the PPV of cytology for
invasive cervical cancer using a cut-oﬀ of severe or worse
cytology is 5.4% in a screening population (aged 20–64).2
The PPV (even at moderate or worse cytology) is even
higher among women aged 40–69 who have not been pre-
viously screened (PPV 21.3%) and women aged 570
(PPV 18.1%). The sensitivity of cytology with a cut-oﬀ
of moderate dyskaryosis or worse for invasive cancer is
89% and 83% respectively, in these high-risk populations,
and levels of inadequate results were low. Thus cytology is
an excellent diﬀerentiator between cancer and non-cancer
among women tested outside routine call and recall for
cervical screening. Furthermore, we show an earlier stage
at diagnosis among women aged 566 with cytology
within 12 months of diagnosis compared with those with
no such cytology, corresponding to a 17–26% reduction in
case fatality. In these high-risk populations, the numbers
of cancers diagnosed per 1000 women tested (2.8 per 1000
in women with their ﬁrst test aged 40–69 and 5.3 per 1000
for women aged 570) are comparable with those identi-
ﬁed by bowel screening (2.0 per 1000 for faecal occult
blood testing)11 and mammographic screening (8.1 per
1000).12
The main strength of this study is that cytology results
were available for the entire population of England, with
data on time since previous screen, which allowed women
with no previous screening results to be identiﬁed,
together with the linked screening histories for women
diagnosed with cervical cancer.
The main limitation is the lack of information on the
reason for the cytology tests. In particular we have no
data on symptoms. However, because this publication
demonstrates high sensitivity and excellent PPV of cytol-
ogy for invasive cancer outside of routine screening, it is
important to publicize the results to stimulate further stu-
dies looking at symptoms speciﬁcally. It is not possible to
rule out reverse causation as a (partial) explanation for the
better stage distribution observed in women with cytology
within a year of diagnosis, for example, if some women
with advanced cancer ﬁrst present with severe symptoms
that lead to diagnosis without cytology. This study reports
cytology read using BSCC terminology in laboratories
Table 1. Result of the first (non-recall) cytology test in the last 12 months in women (a) aged570 and (b) whose first cytology test was at
age 40–69, with cervical cancer (‘Cancers’) and in the general population (‘Cytology tests’) and predictive value (PV) of the test result to
cervical cancer.
a) Aged 570 b) First cytology aged 40–69
Cytology
test result1 Cancers
% cancers
diagnosed with
test result
or worse
Cytology
tests
% of all
tests PV Cancers
% cancers
diagnosed with
test result
or worse
Cytology
tests
% of all
tests PV
Negative 4 100 13071 89.1 0.03% 2 100 84,774 90.8 0.00%
Inadequate 2 95 809 5.5 0.25% 6 99 3,381 3.6 0.18%
Borderline 7* 92 350 2.4 2.00% 14* 97 2,554 2.7 0.55%
Mild 0 83 74 0.5 0.00% 6 92 1,275 1.4 0.47%
Moderate 3 83 21 0.1 14.29% 12 89 311 0.3 3.86%
Severe 8 79 47 0.3 17.02% 108 85 705 0.8 15.32%
?Glandular 11 69 184 1.3 5.98% 10 43 128 0.1 7.81%
?Invasive 43 55 112 0.8 38.39% 101 39 194 0.2 52.06%
Total 78 14668 0.53% 259 93322 0.28%
Moderate or worse 65 83 364 2.5 17.86% 231 89 1338 1.4 17.26%
1First routine cytology test in the last 12 months.
*5/7 and 9/14 were referred to colposcopy based on a single borderline, suggesting that they may have been labelled ‘‘query high grade, equivalent to ASC-H’’.
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Figure 1. ROC curves showing the sensitivity and specificity of each cytology result for cervical cancer (i) in women aged 70þ and (ii) in
women whose first cytology was at age 40–69.
Table 2. Five-year age-adjusted case fatality rates by stage at diagnosis in those aged566 diagnosed April 2007-March 2012 and the possible
reduction if the stage distribution of women with cytology in the 12 months prior to diagnosis was achieved.
Stage 1A 1B 2 3 4
not
recorded Total
Age-adjusted
case fatality
(scenario 1)2
Age-adjusted
case fatality
(scenario 2)3
Crude case
fatality4
Case fatality (%) SEER1a 1.6 16.2 47.4 67.5 89.8
Case fatality (%) Anglia1b 4 4 46 62 95
women with cytology within 12 months of diagnosis aged 566
N 9 44 41 13 14 34 155* 42.0% 39.7% 35.0%
% 5.8 28.4 26.5 8.4 9.0 21.9
women without cytology within 12 months of diagnosis aged 566
N 49 285 373 275 235 398 1615 50.7% 51.0% 47.6%
% 3.0 17.6 23.1 17.0 14.6 24.6
Relative reduction in case fatality (%) 17.3 22.1 26.4
1a100 minus 5-year % relative survival for women aged 70þ, SEER 1988–2001 (see reference 15).
1b100 minus 5-year % relative survival (all ages), Anglia 2002–2006 (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/cervical-cancer/survival#heading-Three).
2Assuming the stage distribution for those with stage not recorded did not depend on having cytology in the year prior to diagnosis and using SEER survival.
3Assuming the stage distribution for those with stage not recorded did depend on having cytology in the year prior to diagnosis and using SEER survival.
4Ignoring those with unrecorded stage and using survival from Anglia.
*78 of these cancers were part of the cohort aged 570 and 10 of the cohort diagnosed within a year of their first cytology test aged 40–69 in Table 1.
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subject to accreditation and quality assurance, and the
conclusions may not be generalizable to other systems
for reporting cytology, or to countries with less quality
assurance. Survival data for England are not available by
both stage and age, and survival for stages 1A and 1B are
combined. Because the proportion of stage 1 cancers that
are stage 1A falls oﬀ rapidly with age, using the average
stage 1 survival grossly overestimates the survival of
women with stage 1 cancer in this study, most of whom
had stage 1B cancer. This led to an overestimation of the
reduction in case fatality associated with cytology in the 12
months before diagnosis. Although survival rates in the
USA are slightly better than in England, this is true for
all stages of diagnosis, and should therefore not unduly
aﬀect the estimated relative reduction in case fatality.
We have studied cytology in women aged 570 and in
women whose ﬁrst cytology was at age 40–69. The cytol-
ogy in these women was unlikely to have been purely for
screening. Based on high rates of prevalent cervical
cancer, we infer that many of these cytology tests are
likely to have been in women with symptoms (why else
would a woman in her 70s have cytology in England?). An
audit of cervical cancers diagnosed in a London hospital
showed that women with ‘symptomatic’ cytology tests
were less likely to have early stage cancer than screen-
detected cancers in asymptomatic women, though more
likely than women without cytology.13
Diagnosing symptomatic cervical cancer in primary
care is challenging, given that gynaecological symptoms
are common in women with non-malignant conditions
(eg. genital infections), but cervical cancer is relatively
rare. This study suggests that cervical cytology could be
an important triage tool for primary care physicians mana-
ging women with gynaecological symptoms. Cervical
cytology in this context should be considered as an add-
itional test to be used alongside the normal investigations
and management of non-speciﬁc gynaecological symptoms
(especially genital infections), and should not be treated in
the same way as screening cytology. We propose that GPs
could be responsible for arranging cytology samples in
women with symptoms who attend an appointment
(preferably to be taken by an experienced smear taker, at
that appointment). Samples collected from symptomatic
women not due for screening should be specially labelled.
The reason cited for not recommending cytology in
symptomatic women is that it may delay diagnosis either
directly, through waiting unnecessarily for the test result,
or, more worryingly, as the result of the false reassurance
provided by a false-negative test.14 However, we found
that women with non-screening cytology prior to diagno-
sis are diagnosed at earlier stages than women without
such cytology. There is no evidence that cytology delayed
the diagnosis of cancer in these women. It is also widely
thought that both cytology and colposcopy are problem-
atic in older women. We have shown here that cytology is
excellent for detecting invasive cancers in older women,
and it appears that older women with abnormal smears
are diagnosed with earlier staged cancers, which is pre-
sumably happening through colposcopy. Older women
could be given a short course of oestrogen prior to col-
poscopy, as is often done currently. If cytology were intro-
duced as a triage test for early identiﬁcation of cervical
cancer in women with symptoms, it would seem rational
to ignore all results reported as less than high grade, unless
the woman was (over)due for screening. Women with a
negative, borderline or mild dyskaryosis result would be
managed as if no cytology had been done. Our proposed
strategy for referral is shown in Box 1. In practice we
suggest that ASC-H, which is rare, should be included
with HSIL, as there is evidence that a small, but not insig-
niﬁcant, proportion of cancers are in women with ASC-
H.2 This strategy would result in 2–3% of symptomatic
women being referred to colposcopy, a tiny addition to the
current workload in England. As shown here, even a nega-
tive cytology does not rule out cancer, and in patients with
unremitting symptoms, referral to a gynaecologist would
still be appropriate.
Conclusion
This study suggests that cervical cytology at a threshold of
HSIL in women being tested outside of routine call and
Box 1. Proposed management of symptomatic women based on cytology result.
BSCC cytology result Bethesda System result Proposed management
Negative Within normal limits Continue to explore cause of symptoms.
Do not rule out cervical cancer.Inadequate* Unsatisfactory*
Borderline dyskaryosis*^ ASC-US*
Mild dyskaryosis* LSIL*
Moderate dyskaryosis HSIL Urgent referral to colposcopy
Severe dyskaryosis HSIL
Query glandular neoplasia AIS Urgent (2 week) referral to colposcopy. Consider differential
diagnosis of endometrial cancer in post-menopausal women
with query glandular neoplasia on cytology
Query squamous cell carcinoma Query invasive
*If the woman was overdue screening, test for HPV DNA on residual sample and refer for colposcopy if HPV positive. ^Borderline test results where high grade
disease cannot be excluded and where no HPV test is reported should be considered for referral to colposcopy.
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recall for cervical screening is an excellent identiﬁer of
cervical cancer, and could facilitate earlier diagnosis. We
believe that the evidence presented warrants evaluation of
cytology as a triage tool in women presenting to primary
care with unexplained gynaecological symptoms.
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